Dermapharm SE Photovoltaikanlage im Sonnenuntergang

Sustainability

CSR reports

CSR reports of the Dermapharm Group

 

The CSR report of the Dermapharm Group is addressed to customers, business partners, shareholders, employees and all other stakeholders who are interested in the values and principles of our company. It covers Dermapharm Holding SE and the companies it controls.

2021

CSR report Dermapharm 2021

download

2020

 

CSR report Dermapharm 2020

download

2019

 

CSR Report Dermapharm 2019

download

2018

 

CSR report Dermapharm 2018

download

GRI index

GRI index for the sustainability report

The following GRI Index is oriented towards the current standards of the Global Reporting Initiative 2016 and partly corresponds to the requirements of the “core“ option. To be precise, the following information correspond to the requirements of “GRI 102: General Disclosures 2016“ with the exception of the codes 102-38, 102-39, 102-42, 102-43, 102-44 and 102-46, for each of which an explanation is given for why they have been left out.

 

GRI Index of content

GRI_Code GRI Description References Comment      
102-1 Name of the organization Dermapharm Holding SE        
102-2 Activities, brands, products, and services 2021 Annual Report, pages 12-16, pages 34-38
2021 CSR Report, pages 6-11
       
102-3 Location of headquarters Lil-Dagover-Ring 7
82031 Grünwald
Germany
       
102-4 Location of operations IR Website, section "company"        
102-5 Ownership and legal form Dermapharm has been listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange since February 9, 2018. At 65.05%, the majority of no-par value shares are owned by Themis Beteiligungs-Aktiengesellschaft. 34.95% of the shares of Dermapharm Holding SE are in free float as defined by Deutsche Börse. Detailed information is available at www.ir.dermapharm.de and in the Annual Report 2021, pages 30-31.        
102-6 Markets served Dermapharm has its headquarters in Grünwald near Munich. The Dermapharm Group maintains development, production and sales sites in Germany. In addition, there are sites in Austria, Switzerland, the Netherlands, Denmark, Italy, Spain, Great Britain, Sweden, Croatia, Bosnia and Herzegovina, Poland, Ukraine, USA, Vietnam, China and Japan. The majority of all preparations from the business unit "Branded pharmaceuticals and other healthcare products" are manufactured in the central production and logistics centre in Brehna. Our products are sold in 56 countries.        
102-7 Scale of the organization In 2021, the Dermapharm Group employed an annual average of 2,373 people. The Group comprises 53 companies, 26 of which are based in Germany (see Annual Report 2021, Organizational Chart page 36). The Dermapharm Group currently has about 1,300 drug approvals.        
102-8 Information on employees and other workers Based on a current data query of all Group companies, the following statistics emerged as of the reporting date of December 31, 2021: Of 2,386 employees, 1,393 were women and 993 were men. 2,025 of the positions were permanent and 244 temporary. 2,046 of the jobs were full-time and 340 were part-time. 80% of the jobs were in Germany, 8% in Spain, 3% in Austria, 3% in Poland, 1% each in China, Italy, Croatia, Switzerland, Ukraine, and <1% in the UK, Bosnia and Herzigoniva, USA, Sweden).        
102-9 Supply chain 2021 Annual Report, Risk Report, pages 58-72        
102-10 Significant changes to the organization and its supply chain No significant changes.        
102-11 Precautionary Principle or approach   No formalized precautionary approach exists yet      
102-12 External initiatives CSR Report 2021, page 32, Section: "Responsible marketing"        
102-13 Membership of associations CSR Report 2021, page 32, Section: "Responsible marketing"        
102-14 Statement from senior decision-maker CSR-Report 2021, page 4, Section: "Foreword by the management board"        
102-15 Key impacts, risks, and opportunities 2021 Annual Report p. 58-72: Risk and Opportunity report
2021 CSR Report, page 4: Foreword
2021 CSR Report: page 11: Sustainability Strategy
       
102-16 Values, principles, standards, and norms of behavior CSR Report 2021, page 5: Foreword
Annual Report 2021, pages 58-72: Risk and Opportunity repor
Annual Report 2021, pages 80-85: Corporate Governance Report
       
102-17 Mechanisms for advice and concerns about ethics CSR Report 2021, pages 30-34: Governance and compliance
Annual Report 2021, pages 58-72: Risk and Opportunity report
Annual Report 2021, pages 80-83: Corporate governance report
       
102-18 Governance structure 2021 Annual Report, page 6, Section "Member of the management board"
2021 Annual Report, pages 78-85: Corporate Governance Statement
       
102-19 Delegating authority 2021 Annual Report, pages 80-85: Corporate Governance Report: Information on Corporate Governance Practices        
102-20 Executive-level responsibility for economic, environmental, and social topics Dr. Hans-Georg Feldmeier, CEO        
102-21 Consulting stakeholders on economic, environmental, and social topics CSR Report 2021, pages 30-34: Governance and compliance        
102-22 Composition of the highest governance body and its committees Annual Report 2021, pages 80-85: Corporate Governance Report
       
102-23 Chair of the highest governance body Annual Report 2021, pages 80-85: Corporate Governance Report        
102-24 Nominating and selecting the highest governance body Annual Report 2021, pages 58-72: Risk and Opportunity report
Annual Report 2021, pages 69-74: Corporate Governance Report
       
102-25 Conflicts of interest Annual Report 2021, pages 58-72: Risk and Opportunity report
Annual Report 2021, pages 80-85: Corporate Governance Report
       
102-26 Role of highest governance body in setting purpose, values, and strategy
Annual Report 2021, pages 9-11: Report of the Supervisory Board
Annual Report 2021, pages 80-85: Corporate Governance Report
Annual Report 2021, page 170: Information on the Executive Board and Supervisory Board
Annual Report 2021, pages 58-72: Risk and Opportunity report
       
102-27 Collective knowledge of highest governance body
Annual Report 2021, pages 80-85: Corporate Governance Report
Annual Report 2021, page 170: Information on the Executive Board and Supervisory Board
       
102-28 Evaluating the highest governance body’s performance Annual Report 2021, pages 34-38: Fundamentals of the Group        
102-29 Identifying and managing economic, environmental, and social impacts Annual Report 2021, pages 58-72: Risk and Opportunity report        
102-30 Effectiveness of risk management processes Annual Report 2021, pages 58-72: Risk and Opportunity report
Annual Report 2021, pages 9-11: Report of the Supervisory Board
       
102-31 Review of economic, environmental, and social topics 2021 Annual Report, pages 58-72: Risk and Opportunity report
2021 Annual Report, pages 9-11: Report of the Supervisory Board
CSR Report 2021, page 11: Sustainability strategy and targets
       
102-32 Highest governance body’s role in sustainability reporting The Board of Management and Supervisory Board are responsible for the final review of the reported sustainability information.        
102-33 Communicating critical concerns Annual Report 2021, pages 58-72: Risk and Opportunity report
Annual Report 2021, pages 80-85: Corporate Governance Report
       
102-34 Nature and total number of critical concerns Annual Report 2021, pages 58-72: Risk and Opportunity report
Annual Report 2021, pages 80-85: Corporate Governance Report
       
102-35 Remuneration policies Annual Report 2021, pages 185-199: Remuneration Report        
102-36 Process for determining remuneration Annual Report 2021, pages 185-199: Remuneration Report        
102-37 Stakeholders’ involvement in remuneration 2021 Annual Report, pages 185-199: Remuneration Report
Voting results of the last Annual General Meeting:
https://ir.dermapharm.de/pdf/Dermapharm_Abstimmungsergebnisse_2021.pdf
       
102-38 Annual total compensation ratio   We do not consider the disclosures required under
GRI Code 102-38 to be material for the assessment of our compensation structures
     
102-39 Percentage increase in annual total compensation ratio   We do not consider the disclosures required under
GRI Code 102-38 to be material for the assessment of our compensation structures
     
102-40 List of stakeholder groups 2021 CSR Report, pages 30-34: Governance and compliance        
102-41 Collective bargaining agreements 26% of our employees are subject to collective bargaining agreements.        
102-42 Identifying and selecting stakeholders   No formalized identification and selection of stakeholders with regard to ESG issues exists yet      
102-43 Approach to stakeholder engagement   There is still no formalized stakeholder engagement with regard to ESG issues      
102-44 Key topics and concerns raised   We take ESG issues and suggestions raised by our stakeholders very seriously. However, there is not yet a systematic identification of important ESG issues of our stakeholders.      
102-45 Entities included in the consolidated financial statements Annual Report 2021, pages 98-102: Principles and scope of consolidation        
102-46 Defining report content and topic Boundaries   There is not yet a systematic procedure for determining and thematically delimiting the content of the report.      
102-47 List of material topics CSR Report 2021, page 11: Sustainability strategy and targets        
102-48 Restatements of information No significant changes.        
102-49 Changes in reporting With the CSR Report 2021, reporting was supplemented with further ESG key figures as well as an initial indicative SDG and GRI index.        
102-50 Reporting period 01.01.2021 to 31.12.2021        
102-51 Date of most recent report 12.04.2022        
102-52 Reporting cycle Annually        
102-53 Contact point for questions regarding the report CSR Report 2021, page 37        
102-54 Claims of reporting in accordance with the GRI Standards The sustainability reporting for the 2021 financial year was prepared in accordance with the GRI standards and meets the requirements of the GRI "Core" option in most respects.        
102-55 GRI content index Available on this page        
102-56 External assurance Dermapharm's CSR report has not been audited.        
             
201-1 Direct economic value generated and distributed Annual Report 2021, pages 150-151: Key figures employees        
    Annual Report 2021, page 2: Key figures economy        
    Annual Report 2021, pages 89-90: Profit and loss account        
    Annual Report 2021, pages 91-92: Cash flow statement        
    Annual Report 2021, pages 47-49: Information by business sector        
    Annual Report 2021, page 150: personell expenses
CSR Report 2021, pages 24-29: Employee related topics
       
201-2 Financial implications and other risks and opportunities due to climate change CSR Report 2021, pages 12-20: Environmental key figures        
    CSR Report 2021, pages 17-20: Water management        
    Annual Report 2021, pages 58-72: Risk and Opportunity report        
201-3 Defined benefit plan obligations and other retirement plans Annual Report 2021, pages 150-151: Key figures employees        
    Annual Report 2021, pages 139-140: Retirement provision        
201-4 Financial assistance received from government Annual Report 2021, pages 121-122: Research and development costs        
    Annual Report 2021, pages 108-109: Property, plant and equipment        
    Annual Report 2021, pages 95-96: Valuation/accounting principles for
Property, plant and equipment
       
205-1 Operations assessed for risks related to corruption Compliance: see Compliance Manual online        
    Annual report 2021, page 80: Declaration of Compliance=Values and Compliance        
    Annual report 2021, pages 185-199: Remuneration Report=Values and Compliance        
    Annual report 2021, page 82: Members of the SB=Values and Compliance        
    Annal report 2021, page 170: Members of the AR=Values and Compliance        
    Annual Report 2021, pages 59-71: Compliance in the Risk and Opportunity report        
    Annual Report 2021, pages 80-85: Compliance in the Corporate Governance Report        
    Annual Report 2021, pages 58-72: Risk and Opportunity report
CSR Report 2021, pages 30-34, Governance and Compliance
       
205-2 Communication and training about anti-corruption policies and procedures Annual Report 2021, pages 58-72: Compliance in the Risk and Opportunity report        
             
    Annual Report 2021, pages 80-85: Compliance in the Corporate Governance Report        
205-3 Confirmed incidents of corruption and actions taken CSR Report 2021, pages 30-34: Governance and compliance        
    Annual Report 2021, pages 58-72: Risk and Opportunity report        
    Annual Report 2021, pages 58-72: Compliance in Risk and Opportunity report        
    Annual Report 2021, pages 80-85: Compliance in the Corporate Governance Report        
206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices CSR Report 2021, pages 30-34: Governance and compliance        
             
301-1 Materials used by weight or volume CSR Report 2021, pages 19-20: Recycled waste materials        
301-2 Recycled input materials used CSR Report 2021, pages 12-20: Efficient resource and energy management        
302-1 Energy consumption within the organization CSR Report 2021, pages 12-20: Environmental concerns        
302-2 Energy consumption outside of the organization CSR Report 2021, pages 12-20: Environmental concerns        
302-4 Reduction of energy consumption CSR Report 2021, page 15: Energy consumption of the Dermapharm Group of Companies        
303-1 Interactions with water as a shared resource CSR Report 2021, pages 19-20 Recycled waste materials        
306-1 Waste generation and significant waste-related impacts CSR Report 2021, pages 19-20: Waste management        
    CSR Report 2021, pages 19-20: Recycled waste materials        
306-2 Management of significant waste-related impacts CSR Report 2021, page 11+pages 12-20: Efficient resource and energy management
CSR Report 2021, pages 19-20: Waste management
       
             
             
403-1 Occupational health and safety management system CSR Report 2021, pages 28-29: Occupational health management        
403-3 Occupational health services CSR Report 2021, pages 28-29: Occupational health management        
403-4 Worker participation, consultation, and communication on occupational health and safety CSR Report 2021, pages 28-29: Safety and operational suggestion scheme        
403-5 Worker training on occupational health and safety CSR Report 2021, pages 24-27: Education and training        
403-6 Promotion of worker health CSR Report 2021, pages 28-29: Occupational health management        
403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships CSR Report 2021, pages 28-29: Occupational health management        
403-9 Work-related injuries CSR Report 2021, pages 28-29: Safety and operational suggestion scheme        
    Annual Report 2021, pages 150-151: Key figures employees        
404-2 Programs for upgrading employee skills and transition assistance programs CSR Report 2021, pages 24-27: Education and training        
405-1 Diversity of governance bodies and employees CSR Report 2021, pages 27-28: Diversity and employee participation        
    2021 annual report, pages 82-84: Objectives of the Supervisory Board for its composition        
    Annual Report 2021, pages 150-151: Key figures employees        
    Annual Report 2021, page 6: Board of Directors/Executive Management (CEO/CFO/CMO/CBDO)        
    Annual report 2021, page 170: Board of Directors/Management/Members of the Supervisory Board        
408-1 Operations and suppliers at significant risk for incidents of child labor
CSR-Report 2021, pages 31-32: Ethical and lawful conduct
       
409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor CSR Report 2021, pages 31-32: Ethical and lawful conduct        
416-1 Assessment of the health and safety impacts of product and service categories CSR Report 2021, page 7: Branded pharmaceuticals and other health products
Annual Report 2021, page 34: Branded pharmaceuticals and other health products
CSR Report 2021, page 11: Sustainability strategy and goals
       

ESG data

Environmental Social Governance

Environment (German-speaking production locations)

Environment 2018 2019 2020 2021
Revenue in EUR million 572.4 700.9 793.8 942.9
Number of employees¹ 1,635 1,857 2,311 2,373
Power consumption* in MWh 10,900 10,855 17,224 16,549
Gas consumption* in MWh 12,515 12,307 19,348 20,562
Water consumption* in thousands of m3 61.8 63.5 85.9 109.0
Wastewater consumption* in thousands of m3 61.2 63.5 85.9 112.4
Waste volume* in t 2,218 4,223 1,589 1,448

*German-speaking production locations only
¹ Number of employees based on average headcount..

A more detailed contextualization of the environmental data can be found in the current CSR Report 2021, pp. 12-20.
       

Environment (non-German-speaking production sites)

Environment 2018 2019 2020 2021
Revenue in EUR million 572.4 700,9 793,8 942,9
Number of employees¹ 1.635 1.857 2.311 2.373
Power consumption* in MWh 9.667 9.428 9.995 9.430
Gas consumption* in MWh 24.659 20.700 23.643 27.214
Water consumption* in thousands of m3 88,4 97,0 91,1 84,7
Wastewater consumption* in thousands of m3 51,7 48,7 47,1 50,9
Waste volume* in t 4.415 4.115 4.179 4.643

*non-German-speaking production locations only
¹ Number of employees based on average headcount..

A more detailed contextualization of the environmental data can be found in the current CSR Report 2021, pp. 12-20.
       

Social

Social 2018 2019 2020 2021
Sales in EUR million 572.4 700.9 793.8 942.9
Number of employees¹ 1,635 1,857 2,311 2,373
Fluctuation rate² 7.6% 6.7% 6.3% 12.8%
Total proportion of women   56.7% 59.9% 58.4%
Proportion of women in management (management level 1 and 2) 46.7% 47.9% 48.9% 47.5%
thereof management level 1     39.3% 26.3%
thereof management level 2     53.8% 50.8%
Proportion of fixed-term contracts 13.6% 10.5% 9.3% 10.2%
Part-time employees 15.9% 13.1% 14.1% 14.1%
Average sick days per employee 16.0 16.9 16.5 16.7
Thousand-man quota (TMQ) 12.0 17.0 16.0 13.3
Number of trainees 39 46 51 51
Number of theses in cooperation with Dermapharm 15 31 53 47
Number of suggestions for improvement via the company suggestion scheme 41 57 93 122
Proportion of employees with severe disabilities 2.1% 2.3% 2.9% 2.6%
Average age 42.9 41.4 42.6 42.5

¹ Number of employees based on average headcount.
² Calculation according to the Schlüter formula on the basis of the headcount at the beginning of the period plus additions.
The Schlüter formula takes into account the fact that the headcount is a key date figure.
The staff departures represent a period variable.

For a more detailed contextualization of the social data, see the current CSR Report 2021, pp. 24-29.
       

Governance

 

Compliance at Dermapharm:

Detailed information on compliance and governance at Dermapharm can be found in our Dermapharm Code of Conduct as well as in the Dermapharm CSR Report 2021.

Maintain high standards:

Dermapharm is committed to the following Good Practices for the pharmaceutical industry:
Good Clinical Practice (GCP)
Good Distribution Practice (GDP)
Good Manufacturing Practice (GMP)
Good Pharmakovigilance Practice  (GVP)

Association memberships:

Dermapharm is a member of the BPI: Member list of the Federal Association of the Pharmaceutical Industry
and at the AKG:  Member list of the Pharmaceutical and Cooperation in Health Care e.V.

No animal testing:

In 2021, no animal testing took place at Dermapharm.

ESG Highlights 

Reports on ESG highlights

Energy-Efficient Buildings

 

Conversion and new buildings for more environmentally friendly production

In Brehna, we have a logistics center that complies with the requirements of "Good Distribution Practice" (GDP), which were adopted by the EU in 2013. The aim of GDP is to ensure high product quality of pharmaceuticals by avoiding counterfeiting and manufacturing errors. Likewise, the new building meets the current energy efficiency criteria for buildings of the German Energy Saving Ordinance (EnEV) 2014, including effective thermal insulation and an air-to-water heat pump as well as active post-cooling ventilation. In addition, the building was equipped with a green roof for reasons of ecology and better thermal insulation. Another special energy feature was also implemented in this third building on the site in Brehna. Pharmaceuticals must normally be stored in the temperature range 15-25 °C. In the increasingly hot summer months, compliance with these storage conditions can only be achieved with costly cooling by means of air-conditioning systems. At mibe, we achieve optimum thermal insulation by means of a green roof and night-time air circulation. By using large fans, we draw cooled outside air into the warehouses during the night hours, thus enabling compliance with temperature limits.


A special highlight for reducing CO2 emissions was the installation of a solar plant in the first quarter of 2021 with a power capacity of 610,000 kWh. This will cover almost 10% of the current electricity consumption at the Brehna site. Furthermore, we achieved even better insulation of the roofing from thermal radiation and lowered voltage peaks. 


With our new building at the subsidiary axicorp, we have an ultra-modern production, warehouse and administration building which, on the one hand, meets the currently valid energy standard (EnEV) 2020 and, on the other hand, has a roof area that is three quarters extensively greened. The usable floor space of over 7,400 m2 extends over two floors in the plant and relies on the latest energy standards. These include a photovoltaic system with a rated output of 99.18 kWp, a green roof covering 3,600 m2 and a ventilation system with heat recovery. In combination with an air-to-water heat pump and a gas condensing boiler, this reduces energy requirements. And fresh water consumption is also reduced by using precipitation water from the roof surfaces for toilet flushing.  


In addition, our subsidiary Melasan in Austria moved into a new administration and production building in the past two years which, in addition to meeting current energy efficiency standards, has a rainwater infiltration system to partially offset the sealing of ground surfaces.


At all other production sites, we also comply with strict environmental protection requirements and continuously adapt to new regulatory requirements. Our production sites are located in designated industrial and commercial zones. Before we acquire a company and thus also take over its sites, we first examine the ecological risks in a due diligence process. Since 2015, all our factories have been certified by an accredited engineering firm through an energy audit in accordance with DIN EN1642. 

Use of raw materials

 

Resource Management at Euromed

Euromed, our Spanish subsidiary and manufacturer of herbal pharmaceuticals, has committed to supporting sustainable agriculture. As such, stringent quality control from raw material to waste disposal is of key importance for Euromed. Its main production facility in Barcelona, which processes more than 5,000 tonnes of biomass into herbal extracts each year, has obtained multiple production certifications including ISO 14001 for ecological sustainability. Among other things, the organic waste generated during production is passed on to companies that generate environmentally friendly energy, is composted, or is used as feed for livestock.

Euromed also focuses on exploiting the full potential of the plants used, for instance its product "Lipidic Sterolic Saw Palmetto Extract" (SPE) which as the name suggests is sourced from saw palmetto. The ripe berries of this wild plant, which is considered endangered, are harvested exclusively in Florida and a small part of Georgia, USA. Euromed operates its own facility close to Lake Okeechobee in Florida so that it can rapidly dry and process the harvested berries. This ensures that they have an optimal fatty acid content and means that the raw material is fully traceable. The residue remaining after fruit extraction is used for recycling products such as natural dyes.

Digital Training Platform

 

Modern continuing education in the new "Dermapharm eCampus"

The idea of ensuring employee development regardless of when or where it takes place is growing in significance, and the COVID-19 pandemic has only accelerated the trend towards e-learning. Consequently, in September 2020, the Company launched "Dermapharm eCampus", its own internal training platform, at selected sites. In doing so, we have not just expanded the existing training and education opportunities on offer to our employees but have also laid the foundation to make established training initiatives (including in-person training) more efficient to implement and easier to document. At present, "Dermapharm eCampus" is being used by just under 500 active employees at six Group sites.

The online courses cover regulatory topics (such as data protection, compliance, occupational health and safety, information security) and specialist subject areas (such as drug safety, various product-specific training courses).

The integrated reporting within the system means that those responsible for specific topics always have an overview of how effective their mandatory training programmes are and can further optimise them where necessary. The certificates awarded after successfully completing training serve both as proof of the employee's individual development and as evidence for external audits. In 2020, a total of more than 300 employees each completed nine mandatory training courses via "Dermapharm eCampus".

The training platform will gradually be rolled out to the other Dermapharm Group sites over the course of 2021, and the range of training on offer will continually be expanded. By 2022, we are planning to integrate four other companies within "Dermapharm eCampus". In addition, all employees already have access to specialist training courses available via the online training portal of the German Pharmaceutical Industry Association (Bundesverband der Pharmazeutischen Industrie e.V., "BPI"), BPIeCampus.

Contact person

Investor Relations & Corporate Communications
Dermapharm Holding SE


Britta Hamberger
Phone: +49 (89) 641 86 – 233
E-Mail: ir@dermapharm.com